Neil W. Hoffman, Ph.D., Partner, Arnall Golden Gregory LLP to Speak at TKG’s The HRSA Proposed 340B Pricing Program Omnibus Guidance
Neil W. Hoffman, Ph.D., Partner, Arnall Golden Gregory LLP to Speak at The Knowledge Group’s The HRSA Proposed 340B Pricing Program Omnibus Guidance: Best Compliance Practices Your Firm Should Know
New York, NY, May 13, 2016 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Neil W. Hoffman, Ph.D., Partner, Arnall Golden Gregory LLP will speak at the Knowledge Group’s webcast entitled: “The HRSA Proposed 340B Pricing Program Omnibus Guidance: Best Compliance Practices Your Firm Should Know.” This event is scheduled for June 14, 2016 from 3:00pm – 5:00pm (ET).
For further details, please visit: https://theknowledgegroup.org/all-events-list/live-webcasts/event-homepage/?event_id=1544
About Neil W. Hoffman, Ph.D.
Neil W. Hoffman, Ph.D., is a partner in the Healthcare Practice. Dr. Hoffman offers niche knowledge of the healthcare and life-sciences industry derived from more than 15 years' experience in providing legal representation to clients operating within this heavily regulated sector of the economy. Dr. Hoffman focuses his practice on providing transactional and regulatory representation to health and life-sciences clients, including hospitals and health systems, long-term care providers, home health providers, and hospice providers, both regional and national, as well as academic medical centers, medical groups, allied professionals, pharmaceutical and device companies, and clinical research organizations. His particular areas of focus include federal and state fraud-and-abuse laws (such as Stark law and the federal Anti-Kickback Statute), healthcare mergers and acquisitions, healthcare lending arrangements, health regulatory due diligence, Medicare/Medicaid reimbursement, privacy and security under the Health Insurance Portability and Accountability Act (HIPAA) and applicable state law, medical-device transactions, and clinical research and applicable regulations of the Food and Drug Administration (FDA). He is experienced in helping clients to structure transactions and service models for regulatory compliance while achieving business objectives.
About Arnall Golden Gregory LLP
Arnall Golden Gregory, with more than 150 attorneys in Atlanta and Washington, DC, employs a “business sensibility” approach, developing a deep understanding of each client’s situation in order to find a customized, cost-sensitive solution. A past recipient of The National Law Journal’s prestigious Midsize Hot List honor, the firm advises on corporate, litigation and restructuring and regulatory matters for numerous industries, including business services, healthcare, life sciences, logistics and transportation, real estate, telecommunications, franchising, financial services, information services, energy, and manufacturing. Since 1949, AGG has been a solutions partner that subscribes to the belief “not if, but how.”
Event Synopsis:
The Health Resources and Services Administration (HRSA) in August 2015 issued a notice proposing guidance under the 340B Drug Pricing Program. The proposal is an attempt to clear up confusion about program rules and eliminate ambiguity in the marketplace for all 340B Program stakeholders. Although the proposed guidance is intended to clarify HRSA’s existing policy interpretations, a significant practical effect is to change the standard for 340B patient eligibility. It would also restrict the number of physicians who could write 340B-eligible prescriptions. The program allows certain participating covered entities and other health care providers to obtain discounted prices on outpatient prescription drugs. These entities are required to prove compliance with 340B program requirements overseen by the HRSA within the Department of Health and Human Services (HHS), and are subject to audit. The “mega” guidance could have significant impact on plans and operations, once the final guidance is published in September 2016. In this two-hour live Webcast, a panel of key thought leaders assembled by The Knowledge Group will provide healthcare practitioners and professionals with an in-depth review of HRSA’s 340B Drug Pricing Program Omnibus Guidance. The panel will also help analyze the possible effects and challenges of the Guidance and will offer a roadmap on how to prepare and what needs to be done in order to ensure compliance.
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
For further details, please visit: https://theknowledgegroup.org/all-events-list/live-webcasts/event-homepage/?event_id=1544
About Neil W. Hoffman, Ph.D.
Neil W. Hoffman, Ph.D., is a partner in the Healthcare Practice. Dr. Hoffman offers niche knowledge of the healthcare and life-sciences industry derived from more than 15 years' experience in providing legal representation to clients operating within this heavily regulated sector of the economy. Dr. Hoffman focuses his practice on providing transactional and regulatory representation to health and life-sciences clients, including hospitals and health systems, long-term care providers, home health providers, and hospice providers, both regional and national, as well as academic medical centers, medical groups, allied professionals, pharmaceutical and device companies, and clinical research organizations. His particular areas of focus include federal and state fraud-and-abuse laws (such as Stark law and the federal Anti-Kickback Statute), healthcare mergers and acquisitions, healthcare lending arrangements, health regulatory due diligence, Medicare/Medicaid reimbursement, privacy and security under the Health Insurance Portability and Accountability Act (HIPAA) and applicable state law, medical-device transactions, and clinical research and applicable regulations of the Food and Drug Administration (FDA). He is experienced in helping clients to structure transactions and service models for regulatory compliance while achieving business objectives.
About Arnall Golden Gregory LLP
Arnall Golden Gregory, with more than 150 attorneys in Atlanta and Washington, DC, employs a “business sensibility” approach, developing a deep understanding of each client’s situation in order to find a customized, cost-sensitive solution. A past recipient of The National Law Journal’s prestigious Midsize Hot List honor, the firm advises on corporate, litigation and restructuring and regulatory matters for numerous industries, including business services, healthcare, life sciences, logistics and transportation, real estate, telecommunications, franchising, financial services, information services, energy, and manufacturing. Since 1949, AGG has been a solutions partner that subscribes to the belief “not if, but how.”
Event Synopsis:
The Health Resources and Services Administration (HRSA) in August 2015 issued a notice proposing guidance under the 340B Drug Pricing Program. The proposal is an attempt to clear up confusion about program rules and eliminate ambiguity in the marketplace for all 340B Program stakeholders. Although the proposed guidance is intended to clarify HRSA’s existing policy interpretations, a significant practical effect is to change the standard for 340B patient eligibility. It would also restrict the number of physicians who could write 340B-eligible prescriptions. The program allows certain participating covered entities and other health care providers to obtain discounted prices on outpatient prescription drugs. These entities are required to prove compliance with 340B program requirements overseen by the HRSA within the Department of Health and Human Services (HHS), and are subject to audit. The “mega” guidance could have significant impact on plans and operations, once the final guidance is published in September 2016. In this two-hour live Webcast, a panel of key thought leaders assembled by The Knowledge Group will provide healthcare practitioners and professionals with an in-depth review of HRSA’s 340B Drug Pricing Program Omnibus Guidance. The panel will also help analyze the possible effects and challenges of the Guidance and will offer a roadmap on how to prepare and what needs to be done in order to ensure compliance.
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories